TABLE 2.
Comparison of titers 1/2 or 1 dilution greater in endpoint of frozen banked sera from undocumented and documented cases of syphilis, tested with CDC synthetic VDRL antigen and with CDC and BDMS reference VDRL antigens
| Syphilis category | No. of specimens
|
|||
|---|---|---|---|---|
| Total | With CDC synthetic VDRL antigen higher | With natural VDRLa antigen higher | With CDC synthetic and natural VDRL antigen endpoints equal | |
| Undocumented | 100 | 85 | 0 | 15 |
| Documented | ||||
| Untreated | ||||
| Primary | 9b | 3 | 2 | 4 |
| Secondary | 20 | 20 | 0 | 0 |
| Latent | 6c | 4 | 0 | 1 |
| Treated | ||||
| Primary | 15d | 10 | 0 | 2 |
| Secondary | 30 | 30 | 0 | 0 |
| Latent | 20e | 17 | 1 | 0 |
| Total | 200 | 169 | 3 | 7 |
Natural VDRL antigen was either CDC reference VDRL (undocumented serum samples) or BDMS VDRL antigen (documented sera).
One sample was nonreactive with TP-PA but reactive with both VDRL antigens.
One sample was reactive with TP-PA but nonreactive with both VDRL antigens.
One sample was reactive with TP-PA but nonreactive with both VDRL antigens, and two samples were nonreactive with TP-PA and both VDRL antigens.
One sample was reactive with TP-PA but nonreactive with both VDRL antigens, and one sample was nonreactive with TP-PA and both VDRL antigens.